Elevated immunoglobulin G antibodies to the proline-rich amino-terminal region of Epstein-Barr virus nuclear antigen-2 in sera from patients with systemic connective tissue diseases and from a subgroup of Sjögren's syndrome patients with pulmonary involvements

Clinical and Experimental Immunology

Volumn 139, Issue 3, 2005, Pages 558-568

  Yamazaki, M ^a,b   Kitamura, R ^a   Kusano, S ^a   Eda, H ^a   Sato, S ^b   Okawa Takatsuji, M ^c   Aotsuka, S ^c   Yanagi, Kazuo ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b DENKA COMPANY LIMITED   (Japan)

^c NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

Epstein Barr virus (EBV) nuclear antigen 2 (EBNA 2); Immunoglobulin G antibodies; Proline rich proteins; Rheumatoid arthritis; Sj gren's syndrome; Systemic lupus erythematosus

Indexed keywords

EPITOPE; EPSTEIN BARR VIRUS ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN 1; EPSTEIN BARR VIRUS ANTIGEN 2; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; PROLINE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANTIBODY TITER; ARTICLE; AUTOIMMUNE DISEASE; CARBOXY TERMINAL SEQUENCE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HYPERGAMMAGLOBULINEMIA; HYPOTHESIS; JAPAN; LUNG DISEASE; MAJOR CLINICAL STUDY; OPTICAL DENSITY; PATHOGENESIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SEQUENCE HOMOLOGY; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS;

ADULT; ANTIBODIES, VIRAL; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; CONNECTIVE TISSUE DISEASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPSTEIN-BARR VIRUS INFECTIONS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; HUMANS; IMMUNOGLOBULIN G; LUNG; LUPUS ERYTHEMATOSUS, SYSTEMIC; SJOGREN'S SYNDROME; STATISTICS, NONPARAMETRIC; VIRAL PROTEINS; VIRUS LATENCY;

EID: 14844314842     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2004.02704.x     Document Type: Article

References (71)

1. Fujinami RS, Nelson JA, Walker L, Oldstone MB. Sequence homology and immunologic cross-reactivity of human cytomegalovirus with HLA-DR beta chain: a means for graft rejection and immunosuppression. J Virol 1988; 62:100-5.
2. Visvanathan K, Zabriskie JB. An overview: molecular mimicry and disease. In: Molecular mimicry, microbes, and autoimmunity (ed. Cunningham MW, Fujinami RS), Washington, DC: ASM Press, 2000:1-16.
3. James JA, Harley JB. B-cell epitope spreading in autoimmunity. Immunol Rev 1998; 164:185.
4. Fujinami RS. Virus-induced autoimmunity through molecular mimicry. Ann NY Acad Sci 1988; 540:210-7.
5. Oldstone MB. Molecular mimicry and autoimmune disease. Cell 1987; 50:819-20.
6. Oldstone MB. Virus-induced autoimmunity: molecular mimicry as a route to autoimmune disease. J Autoimmun 1989; 2 (Suppl.):187-94.
7. Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2002; 2:85-95.
8. Miller SD, Katz-Levy Y, Neville KL, Vanderlugt CL. Virus-induced autoimmunity: epitope spreading to myelin autoepitopes in Theiler's virus infection of the central nervous system. Adv Virus Res 2001; 56:199-217.
9. James JA, Gross T, Scofield RH, Harley JB. Immunoglobulin epitope spreading and autoimmune disease after peptide immunization. Sm B/B′-derived PPPGMRPP and PPPGIRGP induce spliceosome autoimmunity. J Exp Med 1995; 181:453-61.
10. Arbuckle MR, Schilling AR, Harley JB, James JA. A limited lupus anti-spliceosomal response targets a cross-reactive, proline-rich motif. J Autoimmun 1998; 11:431-8.
11. McRae BL, Vanderlugt CL, Dal Canto MC, Miller SD. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J Exp Med 1995; 182:75-85.
12. Goebels N, Hofstetter H, Schmidt S, Brunner C, Wekerle H, Hohlfeld R. Repertoire dynamics of autoreactive T cells in multiple sclerosis patients and healthy subjects: epitope spreading versus clonal persistence. Brain 2000; 123:508-18.
13. Tuohy VK, Kinkel RP. Epitope spreading: a mechanism for progression of autoimmune disease. Arch Immunol Ther Exp (Warsz) 2000; 48:347-51.
14. Tuohy VK, Yu M, Yin L, Kawczak JA et al. The epitope spreading cascade during progression of experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol Rev 1998; 164:93-100.
15. Mahler M, Mierau R, Schlumberger W, Bluthner M. A population of autoantibodies against a centromere-associated protein A major epitope motif cross-reacts with related cryptic epitopes on other nuclear autoantigens and on the Epstein-Barr nuclear antigen 1. J Mol Med 2001; 79:722-31.
16. Mahler M, Mierau R, Genth E, Bluthner M. Development of a CENP-A/CENP-B-specific immune response in a patient with systemic sclerosis. Arthritis Rheum 2002; 46:1866-72.
17. Fox R, Sportsman R, Rhodes G, Luka J, Pearson G, Vaughan J. Rheumatoid arthritis synovial membrane contains a 62,000-molecular-weight protein that shares an antigenic epitope with the Epstein-Barr virus-encoded associated nuclear antigen. J Clin Invest 1986; 77:1539-47.
18. Blaschke S, Schwarz G, Moneke D, Binder L, Muller G, Reuss-Borst M. Epstein-Barr virus infection in peripheral blood mononuclear cells, synovial fluid cells, and synovial membranes of patients with rheumatoid arthritis. J Rheumatol 2000; 27:866-73.
19. Bonneville M, Scotet E, Peyrat MA, Saulquin X, Houssaint E. Epstein-Barr virus and rheumatoid arthritis. Rev Rhum Engl Ed 1998; 65:365-8.
20. Edinger JW, Bonneville M, Scotet E, Houssaint E, Schumacher HR, Posnett DN. EBV gene expression not altered in rheumatoid synovia despite the presence of EBV antigen-specific T cell clones. J Immunol 1999; 162:3694-701.
21. Kouri T, Petersen J, Rhodes G et al. Antibodies to synthetic peptides from Epstein-Barr nuclear antigen-1 in sera of patients with early rheumatoid arthritis and in preillness sera. J Rheumatol 1990; 17:1442-9.
22. Tan EM, Jensen FC, Alspaugh MA, Rabin H. Infection with E. B. virus and rheumatoid arthritis. Lancet 1979; 1:549.
23. Rhodes G, Carson DA, Valbracht J, Houghten R, Vaughan JH. Human immune responses to synthetic peptides from the Epstein-Barr nuclear antigen. J Immunol 1985; 134:211-6.
24. Fox RI, Chilton T, Scott S, Benton L, Howell FV, Vaughan JH. Potential role of Epstein-Barr virus in Sjogren's syndrome. Rheum Dis Clin North Am 1987; 13:275-92.
25. Fox RI, Pearson G, Vaughan JH. Detection of Epstein-Barr virus-associated antigens and DNA in salivary gland biopsies from patients with Sjogren's syndrome. J Immunol 1986; 137:3162-8.
26. Inoue N, Harada S, Miyasaka N, Oya A, Yanagi K. Analysis of antibody titers to Epstein-Barr virus nuclear antigens in sera of patients with Sjogren's syndrome and with rheumatoid arthritis. J Infect Dis 1991; 164:22.
27. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25:1271-7.
28. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23:581-90.
29. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292:344-7.
30. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292:403-7.
31. Kotajima L, Aotsuka S, Sumiya M, Yokohari R, Tojo T, Kasukawa R. Clinical features of patients with juvenile onset mixed connective tissue disease: analysis of data collected in a nationwide collaborative study in Japan. J Rheumatol 1996; 23:1088-94.
32. Inoue N, Kuranari J, Harada S et al. Use of enzyme-linked immunosorbent assays with chimeric fusion proteins to titrate antibodies against Epstein-Barr virus nuclear antigen 1. J Clin Microbiol 1992; 30:1442-8.
33. Bowman SJ. Collaborative research into outcome measures in Sjogren's syndrome. Update on disease assessment. Scand J Rheumatol Supplement (116) 2002; 23-7.
34. Strimlan CV, Rosenow EC III, Divertie MB, Harrison EG Jr. Pulmonary manifestations of Sjogren's syndrome. Chest 1976; 70:354-61.
35. Moutspoules HMTA, Youinou AP. The scope of rheumatic diseases; Sjogren's syndrome. In: Oxford textbook of rheumatology (eds Maddison PJ, Isenberg DA, Woo P, Glass DN). New York-Oxford University Press, 1993:829-41.
36. Reichlin M, Harley JB. Antibodies to Ro (SSA) and the heterogeneity of systemic lupus erythematosus. J Rheumatol 1987; 14 (Suppl. 13):112-7.
37. Vitali C, Bombardieri S, Moutsopoulos HM et al. Preliminary criteria for the classification of Sjogren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum 1993; 36:340-7.
38. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24.
39. Kotajima L, Aotsuka S, Fujimani M et al. Increased levels of matrix metalloproteinase-3 in sera from patients with active lupus nephritis. Clin Exp Rheumatol 1998; 16:409-15.
40. Altschul SF, Madden TL, Schaffer AA et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucl Acids Res 1997; 25:3389-402.
41. Mochizuki T, Kotajima F, Kotajima L et al. Clinical and laboratory features in patients with pulmonary involvement of primary Sjogren's syndrome. Jikei Med J 2002; 49:23-9.
42. Cotes JE. Measurement of transfer factor (diffusing capacity) and its subdivisions. Lung function, 5th edn, Chapter 10. Oxford: Blackwell Scientific Publications, 1979:299-324.
43. Henle W, Henle G, Andersson J et al. Antibody responses to Epstein-Barr virus-determined nuclear antigen (EBNA)-1 and EBNA-2 in acute and chronic Epstein-Barr virus infection. Proc Natl Acad Sci USA 1987; 84:570-4.
44. Seigneurin JM, Lavoue MF, Genoulaz O, Bornkamm GW, Lenoir GM. Antibody response against the Epstein-Barr virus-coded nuclear antigen2 (EBNA2) in different groups of individuals. Int J Cancer 1987; 40:349-53.
45. Harada S, Kamata Y, Ishii Y et al. Maintenance of serum immunoglobulin G antibodies to Epstein-Barr virus (EBV) nuclear antigen 2 in healthy individuals from different age groups in a Japanese population with a high childhood incidence of asymptomatic primary EBV infection. Clin Diagn Lab Immunol 2004; 11:123-30.
46. Masucci G, Mellstedt H, Henle G et al. Relationship between clinical stage, histopathology and antibody titers against the second Epstein-Barr virus nuclear antigen (EBNA-2) in non-Hodgkin's lymphoma patients. Int J Cancer 1989; 43:1017-21.
47. Ito S, Yanagi K. Epstein-Barr virus (EBV) nuclear antigen 1 colocalizes with cellular replication foci in the absence of EBV plasmids. J Virol 2003; 77:3824-31.
48. Kieff E. Epstein-Barr virus and its replication. In: Fields virology (eds Knipe DM, Fields BN, Howley PM), vol. 2, 3rd edn. Philadelphia: Lippincott-Raven, 1996:2343-96.
49. Peng CW, Xue Y, Zhao B, Johannsen E, Kieff E, Harada S. Direct interactions between Epstein-Barr virus leader protein LP and the EBNA2 acidic domain underlie coordinate transcriptional regulation. Proc Natl Acad Sci USA 2004; 101:1033-38.
50. Sculley TB, Walker PJ, Moss DJ, Pope JH. Identification of multiple Epstein-Barr virus-induced nuclear antigens with sera from patients with rheumatoid arthritis. J Virol 1984; 52:88-93.
51. Hazelton RA, Sculley TB, Pope JH. The prevalence of antibodies to an Epstein-Barr virus-induced polypeptide (EBNA-2) in the sera of rheumatoid arthritic families. Br J Rheumatol 1987; 26:193-6.
52. Rickinson AB, Kieff E. Epstein-Barr virus. In: Fields virology (eds Knipe DM, Howley PM), vol. 2, 4th edn. Philadelphia: Lippincott Williams & Wilkins, 2001:2575-627.
53. Rhodes G, Rumpold H, Kurki P, Patrick KM, Carson DA, Vaughan JH. Autoantibodies in infectious mononucleosis have specificity for the glycine-alanine repeating region of the Epstein-Barr virus nuclear antigen. J Exp Med 1987; 165:1026-40.
54. Rumpold H, Rhodes GH, Bloch PL, Carson DA, Vaughan JH. The glycine-alanine repeating region is the major epitope of the Epstein-Barr nuclear antigen-1 (EBNA-1). J Immunol 1987; 138:593-9.
55. Milman G, Scott AL, Cho MS et al. Carboxyl-terminal domain of the Epstein-Barr virus nuclear antigen is highly immunogenic in man. Proc Natl Acad Sci USA 1985; 82:6300-4.
56. Petersen J, Rhodes G, Roudier J, Vaughan JH. Altered immune response to glycine-rich sequences of Epstein-Barr nuclear antigen-1 in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Rheum 1990; 33:993-1000.
57. James JA, Kaufman KM, Farris AD, Taylor-Albert E, Lehman TJ, Harley JB. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest 1997; 100:3019-26.
58. James JA, Neas BR, Moser KL et al. Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure. Arthritis Rheum 2001; 44:1122-6.
59. Sculley DG, Sculley TB, Pope JH. Reactions of sera from patients with rheumatoid arthritis, systemic lupus erythematosus and infectious mononucleosis to Epstein-Barr virus-induced polypeptides. J Gen Virol 1986; 67:2253-8.
60. Incaprera M, Rindi L, Bazzichi A, Garzelli C. Potential role of the Epstein-Barr virus in systemic lupus erythematosus autoimmunity. Clin Exp Rheumatol 1998; 16:289-94.
61. Cook AD, Mackay IR, Cicuttini FM, Rowley MJ. IgG subclasses of antibodies to type II collagen in rheumatoid arthritis differ from those in systemic lupus erythematosus and other connective tissue diseases. J Rheumatol 1997; 24:2090-6.
62. Davies JM, Mackay IR, Rowley MJ. Rheumatoid arthritis sera react with a phage-displayed peptide selected by a monoclonal antibody to type II collagen that has homology to EBNA-1. Autoimmunity 1999; 30:53-9.
63. Baer R, Bankier AT, Biggin MD et al. DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature 1984; 310:207-11.
64. Cohen I. Principles of molecular mimicry and autoimmune diseases. In: Molecular mimicry, microbes, and autoimmunity (eds Cunningham M, Fujinami RS). Washington, DC: ASM Press, 2000:17-26.
65. Fatenejad S, Mamula MJ, Craft J. Role of intermolecular/intrastructural B- and T-cell determinants in the diversification of autoantibodies to ribonucleoprotein particles. Proc Natl Acad Sci USA 1993; 90:1210-4.
66. Gardiner P, Ward C, Allison A et al. Pleuropulmonary abnormalities in primary Sjogren's syndrome. J Rheumatol 1993; 20:831-7.
67. American Thoracic Society/European Respiratory Society (ATS/ERS). American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002; 165:277-304.
68. Scotet E, David-Ameline J, Peyrat MA et al. T cell response to Epstein-Barr virus transactivators in chronic rheumatoid arthritis. J Exp Med 1996; 184:1791-800.
69. Blank M, Shoenfeld Y, Cabilly S, Heldman Y, Fridkin M, Katchalski-Katzir E. Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides. Proc Natl Acad Sci USA 1999; 96:5164-8.
70. Alam A, Lambert N, Lule J et al. Persistence of dominant T cell clones in synovial tissues during rheumatoid arthritis. J Immunol 1996; 156:3480-5.
71. Cook AD, Stockman A, Brand CA et al. Antibodies to type II collagen and HLA disease susceptibility markers in rheumatoid arthritis. Arthritis Rheum 1999; 42:2569-76.